🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Chinese DENOVO PD Registry

Recruitingn/aAges 30 Years - 75 YearsAllXiangya Hospital of Central South University
NCT05767151 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The main objective of this longitudinal, multi-center study is to explore the clinical characteristics of PD and confirm biomarkers for PD evolution or progression.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Participants were diagnosed by MDS Clinical Diagnostic Criteria for PD 2. Disease duration ≤ 2 years at baseline 3. Hoehn-Yahr stage ≤2 at baseline 4. The age of PD patients ranges from 30 to 75 years old 5. Participants were naive to antiparkinsonian therapy 6. Able to Written informed consent Exclusion Criteria: 1. Participants were diagnosed with parkinsonism-syndrome 2. Participants were treated with antiparkinsonian drugs at baseline 3. Participants with cognitive impairment 4. Unable to Written informed consent
💊

What it tests

  • Not listed
📍

Where

1 site
Xiangya Hospital of Central South University
Changsha, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy